Developing RDTs to tackle tropical diseases

Atomo is delighted to announce that the company has secured  $1.38 million in grant funding from the Australian Government to assist in the development and commercialisation of new rapid tests for the detection of dengue and chikungunya viruses.

Half the world’s population live in areas at risk of infection from these two viruses, which are leading causes of illness and death in the tropics and subtropics. Readily transmitted by mosquitoes, there are no vaccines to prevent infection so early detection and treatment is critical to limit the risk of complications and death.

Atomo’s Group CEO John Kelly said, “We are extremely grateful to the Australian government for its commitment to global health innovation and continued support of our company. This funding will help us deliver a much needed, easy-to-use solution for the rapid diagnosis of diseases which impact hundreds of millions of people.”

Atomo will work with a number of Queensland based academic partners to commercialise these new tests and ensure that Australian research and innovation remains at the forefront of global health solutions.

Read the full Press Release >